User: Guest  Login
Title:

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.

Document type:
Article; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Beyranvand Nejad, Elham; Labrie, Camilla; van Elsas, Marit J; Kleinovink, Jan Willem; Mittrücker, Hans-Willi; Franken, Kees L M C; Heink, Sylvia; Korn, Thomas; Arens, Ramon; van Hall, Thorbald; van der Burg, Sjoerd H
Abstract:
BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS: IL-6 and IL-6R blockade was applied in an IL-6-mediated immunotherapy-resistant TC-1 tumor model (TC-1.IL-6) and immunotherapy-sensitive TC-1. CONTROL: Effects on therapeutic vaccination-induced tum...     »
Journal title abbreviation:
J Immunother Cancer
Year:
2021
Journal volume:
9
Journal issue:
4
Fulltext / DOI:
doi:10.1136/jitc-2021-002460
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/33879600
TUM Institution:
Molekulare Immunologie (Prof. Knolle); Neurologische Klinik und Poliklinik
 BibTeX